Table 1.

Overview over different assay principles and commercial SARS-CoV-2 antibody tests in comparison to CoVRapid CL-MIA (n.s., not specified)

Assay principle	Test, manufacturer	Used antigen	Assay duration	Specificity in %	Sensitivity in %	Literature
Lateral flow assay	Panbio™ COVID-19 IgG/IgM Rapid Test Device, Abbott Laboratories	n.s.	10–20 min	99.4	93.0	[13]
	STANDARD™ Q COVID-19 IgM/IgG Duo Test, SD Biosensor Inc	N	15 min	100	64.9	[14]
Enzyme-linked immunosorbent assay (ELISA)	SARS-CoV-2 ELISA IgG, EUROIMMUN AG	S1	2 h	98	82.5	[14]
	EDI™ Novel Coronavirus COVID-19 IgG ELISA, Epitope Diagnostics Inc	N, S	< 2 h	98	85.6	[14]
Chemiluminescence immunoassay (CLIA)	MAGLUMI 2019-nCoV IgG, Shenzhen New Industries Biomedical Engineering Co	n.s.	n.s.	88.9–98	70.1–95.0	[14, 15]
	LIAISON® SARS-CoV-2 S1/S2 IgG, DiaSorin S.p.A	S1, S2	35 min	96.8–99	81.4–82.4	[14, 15]
	iFlash-SARS-CoV-2, Shenzhen Yhlo Biotech Co. Ltd.	N, S	> 12 min	92.9–100	76.9–93.0	[15, 16]
	SARS-CoV-2 IgG, Abbott Laboratories	N	29 min	99–100	64.5–92.6	[13, 14, 16]
	Elecsys® Anti-SARS-CoV-2, Roche Diagnostics GmbH	N	18 min	100	80.5–83.5	[14, 16]
Microarray immunoassay (MIA)	xMAP SARS-CoV-2 Multi-Antigen IgG Assay, Luminex Corporation	N, S1, RBD	2.5 h	99.3	96.3	[17, 18]
	CoVRapid CL-MIA, Technical University of Munich	N, S1, RBD	8 min	100	100	This work